Wellgistics Health Inc. has announced a new strategic collaboration with TheracosBio to expand nationwide access to Brenzavvy® (bexagliflozin), an FDA-approved therapy for type 2 diabetes. The agreement will make Brenzavvy available through Wellgistics Health's network of more than 6,500 independent and chain pharmacies across the United States, as well as through direct-to-patient delivery channels. The initiative leverages Wellgistics Health's technology-enabled distribution platform to bypass traditional intermediaries, aiming to reduce costs and improve affordability for patients. The rollout is scheduled to begin in the fourth quarter of 2025, and participating pharmacies will provide patient counseling, adherence support, and care coordination as part of the program.